Dashboard
Manage Tickers

CMPSCOMPASS Pathways plc

Nasdaq compasspathways.com


$ 8.47 $ -0.04 (-0.47 %)    

Wednesday, 08-May-2024 15:59:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 8.5
$ 8.80
$ 0.00 x 0
$ 0.00 x 0
$ 8.23 - $ 9.57
$ 5.01 - $ 12.75
806,532
na
545.89M
$ 1.58
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

compass-pathways-reports-q1-cash-and-cash-equivalents-of-2629m
Compass Pathways Reports Q1 Cash And Cash ...
05/08/2024 10:54:44

Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million. The ...

compass-pathways-q1-2024-gaap-eps-055-misses-048-estimate
Compass Pathways Q1 2024 GAAP EPS $(0.55) ...
05/08/2024 10:52:59

compass-pathways-announced-topline-results-from-an-open-label-phase-2-study-of-comp360-psilocybin-treatment-for-post-traumatic-stress-disorder-the-study-met-its-primary-safety-endpoint-and-available-secondary-efficacy-endpoints
Compass Pathways Announced Topline Results...
05/08/2024 10:41:00

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clin...

Core News & Articles
"FDA Expert Committee Will Review MDMA-Ass...
05/07/2024 15:54:11

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

compass-pathways-mindful-health-solutions-enter-research-collaboration-agreement-to-inform-development-of--scalable-and-cost-effective-delivery-model-for-comp360-psilocybin-treatment
Compass Pathways, Mindful Health Solutions...
05/02/2024 10:44:10

This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deli...

cantor-fitzgerald-reiterates-overweight-on-compass-pathways
Cantor Fitzgerald Reiterates Overweight on...
04/30/2024 14:16:35

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

compass-pathways-and-journey-clinical-have-collaborated-to-inform-development-of-scalable-and-practical-delivery-and-healthcare-provider-training-model-for-comp360-psilocybin-treatment-if-approved-for-treatment-resistant-depression
Compass Pathways And Journey Clinical Have...
04/29/2024 10:38:05

cantor-fitzgerald-reiterates-overweight-on-compass-pathways
Cantor Fitzgerald Reiterates Overweight on...
04/19/2024 14:40:52

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

cantor-fitzgerald-reiterates-overweight-on-compass-pathways
Cantor Fitzgerald Reiterates Overweight on...
04/18/2024 14:05:17

Cantor Fitzgerald analyst Charles Duncan reiterates Compass Pathways (NASDAQ:CMPS) with a Overweight.

psyched-dea-revisits-ban-on-two-psychedelics-farewell-russell-newcombe-podcast-episode-on-kanna--more
Psyched: DEA Revisits Ban On Two Psychedel...
04/17/2024 12:42:33

whos-who-in-cannabis-latest-executive-changes-you-should-know-about
Who's Who In Cannabis: Latest Executive Ch...
04/16/2024 00:22:56

micron-iris-energy-tripcom-group-and-other-big-stocks-moving-higher-on-monday
Micron, Iris Energy, Trip.com Group And Ot...
04/01/2024 17:02:28

U.S. stocks were lower, with the Dow Jones falling around 250 points on Monday.

morgan-stanley-initiates-coverage-on-compass-pathways-with-overweight-rating-announces-price-target-of-30
Morgan Stanley Initiates Coverage On Compa...
04/01/2024 10:49:20

Morgan Stanley analyst Vikram Purohit initiates coverage on Compass Pathways (NASDAQ:CMPS) with a Overweight rating and anno...

psychedelics-headlines-a-form-of-life-treating-chronic-pain-microdosing-and-more
Psychedelics Headlines: A Form Of Life, Tr...
03/30/2024 12:57:44

psyched-5-meo-dmt-for-depression-utah-hospitals-providing-therapy-elon-musk-and-metas-influence
Psyched: 5-MeO-DMT For Depression, Utah Ho...
03/29/2024 16:43:17

atai-life-sciences-q4-and-full-year-2023-results-steep-cash-drain-yet-2026-target-remains-update-on-psychedelic-pipeline
Atai Life Sciences Q4 And Full-Year 2023 R...
03/29/2024 13:20:35

compass-pathways-board-chair-and-co-founder-george-goldsmith-and-co-founder-ekaterina-malievskaia-step-down-from-board-of-directors-effective-march-29-2024
Compass Pathways Board Chair And Co-Founde...
03/28/2024 12:09:41

Compass Pathways plc (NASDAQ:CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evi...

psyched-lsd-psilocybin-as-breakthrough-therapies-14m-fed-grant-for-ibogaine-indianas-research-and-more
Psyched: LSD, Psilocybin As Breakthrough T...
03/20/2024 18:49:36

Core News & Articles
Reported Earlier, 'Indiana Lawmakers Send ...
03/14/2024 16:42:38

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-announces-positive-clinical-data--canadian-150m-private-placement
FDA Grants Cybin Breakthrough Therapy Stat...
03/13/2024 15:33:50

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION